Natera, Inc. (NASDAQ:NTRA) Receives $175.76 Average PT from Analysts

Natera, Inc. (NASDAQ:NTRA) has earned a consensus recommendation of “Buy” from the sixteen brokerages that are covering the firm, MarketBeat reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued a report on the stock in the last year is $175.76.

Several brokerages recently commented on NTRA. Piper Sandler increased their price target on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Canaccord Genuity Group restated a “buy” rating and set a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, March 19th. BTIG Research reaffirmed a “buy” rating on shares of Natera in a report on Friday, February 28th. Finally, Sanford C. Bernstein boosted their price target on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th.

Natera Stock Up 0.5 %

Shares of NASDAQ NTRA opened at $157.38 on Friday. Natera has a 1 year low of $92.14 and a 1 year high of $183.00. The firm’s 50-day moving average is $146.87 and its 200-day moving average is $154.84. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $21.28 billion, a PE ratio of -89.42 and a beta of 1.80.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Equities analysts expect that Natera will post -1.49 EPS for the current year.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 663 shares of the company’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. This represents a 0.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $151.61, for a total value of $606,440.00. Following the completion of the transaction, the director now owns 9,704 shares in the company, valued at approximately $1,471,223.44. The trade was a 29.19 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 153,099 shares of company stock valued at $22,136,941. 7.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Principal Securities Inc. lifted its stake in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 59 shares during the last quarter. Gladstone Institutional Advisory LLC grew its position in Natera by 1.7% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock worth $574,000 after acquiring an additional 61 shares during the last quarter. Fulton Bank N.A. increased its holdings in Natera by 2.0% in the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company’s stock worth $516,000 after purchasing an additional 71 shares in the last quarter. QRG Capital Management Inc. raised its position in Natera by 1.5% in the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company’s stock valued at $766,000 after purchasing an additional 81 shares during the last quarter. Finally, Bridges Investment Management Inc. boosted its stake in shares of Natera by 5.5% during the first quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 87 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.